Literature DB >> 18091568

Role of host defense peptides of the innate immune response in sepsis.

Tobias Hirsch1, Marie Metzig, Andreas Niederbichler, Hans-Ulrich Steinau, Elof Eriksson, Lars Steinstraesser.   

Abstract

Innate immune response and its effector molecules have received growing attention in research. Host defense peptides are known to be antimicrobially active. Recently, the peptides have been recognized as potent signaling molecules for cellular effectors of both innate and adaptive immunity. Mammalian peptides in particular revealed immunomodulatory functions, including endotoxin-binding and -neutralizing capacity, chemotactic activities, induction of cytokines and chemokines, promotion of wound healing, and angiogenesis. In sepsis, they present a family of natural substances that can be used in combination with antibiotics to complete a broad-spectrum antimicrobial regimen with endotoxin-neutralizing properties. Although there are side effects, host defense peptides have the potential to be significant reinforcements to the currently available therapeutic options in the future. In this review, we analyze the role of host defense peptides in infection and immune response, and discuss recent efforts to establish host defense peptides as potent novel therapeutic agents for the treatment of sepsis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18091568     DOI: 10.1097/shk.0b013e318160de11

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  8 in total

1.  Natural History of Innate Host Defense Peptides.

Authors:  A Linde; B Wachter; O P Höner; L Dib; C Ross; A R Tamayo; F Blecha; T Melgarejo
Journal:  Probiotics Antimicrob Proteins       Date:  2009-12       Impact factor: 4.609

Review 2.  Role of innate host defenses in susceptibility to early-onset neonatal sepsis.

Authors:  James L Wynn; Ofer Levy
Journal:  Clin Perinatol       Date:  2010-06       Impact factor: 3.430

3.  Host defense peptides of thrombin modulate inflammation and coagulation in endotoxin-mediated shock and Pseudomonas aeruginosa sepsis.

Authors:  Martina Kalle; Praveen Papareddy; Gopinath Kasetty; Matthias Mörgelin; Mariena J A van der Plas; Victoria Rydengård; Martin Malmsten; Barbara Albiger; Artur Schmidtchen
Journal:  PLoS One       Date:  2012-12-13       Impact factor: 3.240

4.  A family of helminth molecules that modulate innate cell responses via molecular mimicry of host antimicrobial peptides.

Authors:  Mark W Robinson; Sheila Donnelly; Andrew T Hutchinson; Joyce To; Nicole L Taylor; Raymond S Norton; Matthew A Perugini; John P Dalton
Journal:  PLoS Pathog       Date:  2011-05-12       Impact factor: 6.823

5.  Exploring the pharmacological potential of promiscuous host-defense peptides: from natural screenings to biotechnological applications.

Authors:  Osmar N Silva; Kelly C L Mulder; Aulus E A D Barbosa; Anselmo J Otero-Gonzalez; Carlos Lopez-Abarrategui; Taia M B Rezende; Simoni C Dias; Octávio L Franco
Journal:  Front Microbiol       Date:  2011-11-22       Impact factor: 5.640

Review 6.  Antifungal Peptides as Therapeutic Agents.

Authors:  Miguel Fernández de Ullivarri; Sara Arbulu; Enriqueta Garcia-Gutierrez; Paul D Cotter
Journal:  Front Cell Infect Microbiol       Date:  2020-03-17       Impact factor: 5.293

Review 7.  ECM-based materials in cardiovascular applications: Inherent healing potential and augmentation of native regenerative processes.

Authors:  Anna V Piterina; Aidan J Cloonan; Claire L Meaney; Laura M Davis; Anthony Callanan; Michael T Walsh; Tim M McGloughlin
Journal:  Int J Mol Sci       Date:  2009-11-20       Impact factor: 6.208

8.  Cathelicidin-like helminth defence molecules (HDMs): absence of cytotoxic, anti-microbial and anti-protozoan activities imply a specific adaptation to immune modulation.

Authors:  Karine Thivierge; Sophie Cotton; Deborah A Schaefer; Michael W Riggs; Joyce To; Maria E Lund; Mark W Robinson; John P Dalton; Sheila M Donnelly
Journal:  PLoS Negl Trop Dis       Date:  2013-07-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.